Home › Type 2 Diabetes › Utah › Ogden
Type 2 Diabetes clinical trials in Ogden, UT
4 studies for Type 2 Diabetes are looking for participants at sites in and around Ogden (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
RecruitingPhase 2
- Ogden Clinic - Canyon View, Ogden
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
RecruitingPhase 3
- Ogden Clinic - Canyon View, Ogden
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
RecruitingPhase 3
- Research Site, Ogden
AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
RecruitingPhase 3
- Alpine Research Association, Layton · 11 mi away
About Type 2 Diabetes
Type 2 Diabetes, previously referred to as Adult Onset Diabetes, is the more common type. Risk factors include obesity and family history.
More about Type 2 Diabetes on MedlinePlus
Type 2 Diabetes trials in other cities
- San Antonio, TX36 studies
- Houston, TX30 studies
- Orlando, FL24 studies
- Boston, MA20 studies
- Miami, FL19 studies
- Chicago, IL19 studies
- Columbus, OH18 studies
- Dallas, TX18 studies
- Atlanta, GA17 studies
- Las Vegas, NV17 studies
- Birmingham, AL16 studies
- New York City, NY16 studies
Other studies in Ogden
- Obesity6 studies
- Overweight5 studies
- Cardiovascular Disease4 studies
- Pneumococcal Infections3 studies
- Heart Failure3 studies
- COPD3 studies
- Atherosclerosis3 studies
- Major Depressive Disorder3 studies
- Ulcerative Colitis3 studies
- Crohn's Disease3 studies
- Migraine3 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.